Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.

Muskan Agarwal,Alex Liu,Daniel Almquist,Blake T Langlais,Konstantinos Leventakos,Nathan Y Yu,Rami Manochakian,Vinicius Ernani

Cancer（2023）

引用 0|浏览23

暂无评分

摘要

The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2-3 and ECOG PS 0-1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES-SCLC with an ECOG PS of 2-3.

查看译文

关键词

chemoimmunotherapy, chemotherapy, eastern cooperative oncology group performance status, extensive-stage small cell lung cancer, overall survival, progression-free survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要